Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response
- 1 February 2015
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 24 (1) , 3-11
Abstract
No abstract availableKeywords
Funding Information
- Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (Contract No. HHSA 290201200014I)
This publication has 40 references indexed in Scilit:
- 18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast CancerJournal of Nuclear Medicine, 2013
- 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast CancerJournal of Nuclear Medicine, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast CancerJournal of Clinical Oncology, 2008
- [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Monitoring primary breast cancer throughout chemotherapy using FDG-PETBreast Cancer Research and Treatment, 2006
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000